60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · IEX Real-Time Price · USD
0.246
-0.004 (-1.44%)
At close: Apr 18, 2024, 3:59 PM
0.248
+0.001 (0.57%)
After-hours: Apr 18, 2024, 7:44 PM EDT
Company Description
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.
The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.
60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.
60 Degrees Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 12, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Dr. Geoffrey Stuart Dow |
Contact Details
Address: 1025 Connecticut Avenue Nw, Suite 1000 Washington, District of Columbia 20036 United States | |
| Phone | 202-327-5422 |
| Website | 60degreespharma.com |
Stock Details
| Ticker Symbol | SXTP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.30 |
| CIK Code | 0001946563 |
| ISIN Number | US83006G1040 |
| Employer ID | 45-2406880 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Geoffrey Stuart Dow | Chairman, Chief Executive Officer and President |
| Tyrone Miller | Chief Financial Officer and Treasurer |
| Dr. Bryan Smith | Chief Medical Officer |
| Kristen Landon | Chief Commercial Officer |
| Jennifer Herz | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 15, 2024 | 8-K | Current Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 2, 2024 | 8-K | Current Report |
| Jan 31, 2024 | 424B4 | Prospectus |
| Jan 29, 2024 | EFFECT | Notice of Effectiveness |
| Jan 22, 2024 | 8-K | Current Report |
| Jan 22, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jan 18, 2024 | UPLOAD | Filing |